New polyethylene glycol (PEG) powder portfolio, supported by European partnerships and dedicated technical support, enhances process efficiency for highly regulated pharmaceutical applications.
Indovinya, the global specialty chemicals and surfactants division of Indorama Ventures, announced the strategic launch of its OXIPURITY® 4000 P (Polyethylene Glycols in Powder) portfolio across the Europe, Middle East, and Africa regions. The expansion marks an important step in strengthening the company’s footprint in the highly regulated pharmaceutical excipients market in the region.
Designed to meet the stringent requirements of both the European Pharmacopoeia (EP) and the U.S. Pharmacopeia (USP), the OXIPURITY® 4000 P portfolio supports consistent manufacturing performance and high product quality. The introduction of PEG in powder form expands Indovinya’s ability to serve solid dosage applications, enabling pharmaceutical companies to optimize their production processes.
“Our OXIPURITY Powder launch is supported by European partners and a dedicated structure of R&D and technical experts, combining deep chemical expertise with functionalities know-how to support customers in developing pharmaceutical products.” said Fabiana Marra, Marketing and R&D Director at Indovinya.
Enhancing Efficiency and Supporting Regulatory Compliance
The quality of solid dosage forms is closely linked to powder performance. OXIPURITY® 4000 P has been developed to address key industry needs, including:
- Improved flowability, enabling stable manufacturing speeds and reduced weight variation
- Controlled particle characteristics, supporting better API distribution and formulation consistency
- High regulatory standards, with production aligned to Good Manufacturing Practice (GMP), ensuring safety and traceability across the value chain
Partnering with Indovinya from the early stages of formulation development enables customers to navigate regulatory requirements, optimize product performance, and bring innovative pharmaceutical solutions to market faster.
“Our goal is to simplify both sourcing and formulation through proximity and partnership, offering customers reliable access to high-quality excipients backed by strong technical expertise,” Marra added.
Indovinya will also participate in CPHI Milan Europe, where visitors can meet the team at booth #1H10 and learn more about the company’s Nutrition & Health portfolio, including the newly launched OXIPURITY® 4000 P. Participation in the event reinforces Indovinya’s commitment to delivering high-quality and high-performance solutions for pharmaceutical applications.
About Indorama Ventures
Indorama Ventures PCL, listed in Thailand (Bloomberg: IVL.TB), is one of the world’s leading sustainable petrochemicals producers, with a manufacturing footprint serving local and regional customers across Europe, Africa, the Americas, and the Asia Pacific. Our ~25,000 employees reimagine chemistry to create safe, responsible materials that sustain life-critical industries and improve the lives of billions of people. Our segments—Combined PET, Fibers, Indovinya, and Indovida—produce indispensable chemistry serving essential markets, including food & beverages, textiles, pharmaceuticals, home & personal care, automotive, and agrochemicals. The company’s diverse businesses generated revenue of $13.6 billion in 2025. Indorama Ventures is listed in the Dow Jones Best-In-Class Indices, recognising our ambition to lead change and shape a future in which materials are more innovative and circular.
